CVS rallies on turnaround momentum and EPS growth, while CI is a defensive play with stable returns and a focused healthcare ...

The rise of new challengers is placing new pressure on publicly traded incumbents, which are deeply embedded in the traditional layers of healthcare.

Wellgistics Health, Inc. (NASDAQ:WGRX), a healthcare infrastructure company transforming the prescription drug ecosystem, today announced key additions to its executive leadership team and Board of ...

UBS analyst AJ Rice reaffirmed a “Buy” rating on The Cigna Group (NYSE:CI) with a price target of $390. Rice shared his views ...

In 2023, Sheldon Ekirch was diagnosed with small fiber neuropathy, which makes her limbs and muscles feel as if they’re on ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Hims & Hers stock took a nosedive after Cigna’s Evernorth division announced a $200 monthly cap on popular weight-loss drugs ...

The president of one of the development partners called the groundbreaking an “important milestone,” while the fate of federal funding for other affordable projects is unknown.

The agreements cap patients’ monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs ...

Evernorth has capped antiobesity drug monthly co-pays at $200 in a move to improve access and affordability amid new drug ...

Shares of telehealth provider Hims & Hers Health Inc. (HIMS) dropped over 3% on Thursday after Cigna Group’s (CI) Evernorth ...

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.